The National Institutes of Health failed to insure that all clinical trials funded by the agency and required to be reported in 2019 and 2020 met federal requirements, according to an inspector general report released Tuesday.
The Department of Health and Human Services Office of Inspector General reviewed a total of 72 such trials from that period and found results were never submitted in 25, late in 12 and on time in 35.
The Department of Health and Human Services will invest $3.2 billion to develop and manufacture COVID-19 antiviral medicines, it announced Thursday.
The initiative, funded as part of the American Rescue Plan, is designed to accelerate research into antivirals as well as build platforms for urgent response to future viral threats, the Department of Health and Human Services (HHS) said in a statement Thursday. Specifically, the plan expands antiviral clinical trials, forms partnerships between health agencies and pharmaceutical companies, and funds “drug discovery groups” tasked with innovating new antiviral medicines.
“New antivirals that prevent serious COVID-19 illness and death, especially oral drugs that could be taken at home early in the course of disease, would be powerful tools for battling the pandemic and saving lives,” said chief medical adviser Dr. Anthony Fauci in the statement.